Trial Profile

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; EIK 1001 (Primary) ; Glycopyranosyl lipid adjuvant (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
Focus Therapeutic Use
Acronyms AGADIR

Most Recent Events

30 Apr 2025 Results (n=41) assessing safety and efficacy of atezolizumab, EIK1001, and radiotherapy in virus-associated tumors presented at the 116th Annual Meeting of the American Association for Cancer Research
27 Sep 2023 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.
27 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com